Phase 2 Trial Miss and Shareholder Investigation Weigh on Biogen

What happened

Biogen shares fell 6.4% after Phase 2 CELIA trial data for diranersen missed its primary dose-response endpoint, prompting a shareholder investigation. The miss adds to pipeline execution concerns beyond the company's core rare-disease and Alzheimer's launches. However, near-term revenue drivers—Leqembi, Skyclarys, and Zurzuvae—remain on track and are the primary focus of the current investment thesis. The CELIA setback introduces incremental uncertainty around Biogen's broader rare-disease pipeline, but does not fundamentally alter the revenue stabilization narrative. Investors now face a slightly higher risk profile for the pipeline component of the story, requiring patience until 2026 guidance and additional commercial data clarify the trajectory.

Implication

The CELIA miss is a tangible negative for Biogen's pipeline credibility, but the investment thesis has always centered on the success of Leqembi, Skyclarys, and other launched assets to offset MS decline. This trial failure does not change those revenue assumptions, but it does increase the probability of the bear case (30% probability, $160 implied value). Investors should monitor upcoming quarters for Leqembi and Skyclarys momentum, and await 2026 guidance for confirmation of revenue stabilization. If the core launches continue to perform, the stock's valuation remains supported; if pipeline concerns compound with commercial disappointments, downside toward the high-$150s becomes more likely. A disciplined approach is to hold at current levels and reassess after FY2025 results and 2026 outlook.

Thesis delta

The Phase 2 CELIA miss adds to pipeline risk but does not alter the core investment thesis, which already assigned a WAIT rating and did not rely on diranersen. The bear case probability edges higher as pipeline execution uncertainty increases, but the stock's valuation still hinges on commercial launches and MS erosion trends.